Summary by Moomoo AI
Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, announced on April 17, 2024, an exclusive licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. This agreement grants Clearmind exclusive worldwide rights to develop, research, manufacture, market, and commercialize products based on a patent-pending synthesis of Generation 3.0 psychedelic compounds. These compounds are aimed at treating addiction and mental disorders, with a focus on safety and therapeutic potential. The CEO of Clearmind, Dr. Adi Zuloff-Shani, emphasized the company's commitment to innovation and its goal to provide optimized psychedelic medications for patients with unmet needs. The announcement was made in a press release which is also incorporated by reference into the company's Registration Statements on Form F-3 filed with the SEC. Clearmind's shares are traded on Nasdaq and the Frankfurt Stock Exchange under the symbols 'CMND' and 'CWY0', respectively.